Your browser doesn't support javascript.
loading
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
Lawitz, Eric; Sulkowski, Mark S; Ghalib, Reem; Rodriguez-Torres, Maribel; Younossi, Zobair M; Corregidor, Ana; DeJesus, Edwin; Pearlman, Brian; Rabinovitz, Mordechai; Gitlin, Norman; Lim, Joseph K; Pockros, Paul J; Scott, John D; Fevery, Bart; Lambrecht, Tom; Ouwerkerk-Mahadevan, Sivi; Callewaert, Katleen; Symonds, William T; Picchio, Gaston; Lindsay, Karen L; Beumont, Maria; Jacobson, Ira M.
Affiliation
  • Lawitz E; Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA. Electronic address: lawitz@txliver.com.
  • Sulkowski MS; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Ghalib R; Texas Clinical Research Institute, Arlington, TX, USA.
  • Rodriguez-Torres M; Fundación de Investigación, San Juan, PR, USA.
  • Younossi ZM; Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA.
  • Corregidor A; Borland-Groover Clinic, Jacksonville, FL, USA.
  • DeJesus E; Orlando Immunology Center, Orlando, FL, USA.
  • Pearlman B; Atlanta Medical Center, Atlanta, GA, USA.
  • Rabinovitz M; University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Gitlin N; Atlanta Gastroenterology Association, Atlanta, GA, USA.
  • Lim JK; Yale Liver Center and Yale University School of Medicine, New Haven, CT, USA.
  • Pockros PJ; Scripps Clinic, La Jolla, CA, USA.
  • Scott JD; Harborview Medical Center, Seattle, WA, USA.
  • Fevery B; Janssen Research & Development, Beerse, Belgium.
  • Lambrecht T; Novellas Healthcare, Zellik, Belgium.
  • Ouwerkerk-Mahadevan S; Janssen Research & Development, Beerse, Belgium.
  • Callewaert K; Janssen Research & Development, Beerse, Belgium.
  • Symonds WT; Gilead Sciences Inc, Foster City, CA, USA.
  • Picchio G; Janssen Research & Development, Titusville, NJ, USA.
  • Lindsay KL; Janssen Research & Development, Titusville, NJ, USA.
  • Beumont M; Janssen Research & Development, Beerse, Belgium.
  • Jacobson IM; Weill Cornell Medical College, New York, NY, USA.
Lancet ; 384(9956): 1756-65, 2014 Nov 15.
Article in En | MEDLINE | ID: mdl-25078309
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sulfonamides / Uridine Monophosphate / Hepacivirus / Hepatitis C, Chronic / Heterocyclic Compounds, 3-Ring Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Lancet Year: 2014 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sulfonamides / Uridine Monophosphate / Hepacivirus / Hepatitis C, Chronic / Heterocyclic Compounds, 3-Ring Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Lancet Year: 2014 Document type: Article